Treatment of PBMCs with 3 μM danazol concurrent with EBV infection led to an increase in the number of CD19+ proliferating B cells at day 7 post-infection relative to untreated cells (Figure 3B). The gene discussed is CD19; the disease is Epstein-Barr virus infection.